EFFECTS OF ALEGLITAZAR ON CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH STAGE 3 CHRONIC KIDNEY DISEASE AND TYPE II DIABETES

✍ Scribed by Malmberg, Klas; Hanefeld, Markolf; Ruilope, Luis; Lincoff, A.; Viberti, Giancarlo; Mudie, Nadejda; Urbanowska, Teresa

• Book ID: 121940360
• Publisher: Elsevier Science
• Year: 2013
• Tongue: English
• Weight: 156 KB
• Volume: 61
• Category: Article
• ISSN: 1558-3597
• DOI: 10.1016/S0735-1097(13)61173-0